Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyMeta-analysis on the effects of octreotide on tumor mass in acromegalyRapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionClinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients.Medical therapy of acromegalyLong-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.Current pharmacotherapy for acromegaly: a review.Treatment strategies for acromegaly.The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.Etiologic aspects and management of acromegaly.Resistance to somatostatin analogs in acromegaly: an evolving concept?Newer options in the management of acromegaly.Changing paradigms in the surgical and medical management of acromegaly.Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.From somatostatin to octreotide LAR: evolution of a somatostatin analogueNanomedicines in the treatment of acromegaly: focus on pegvisomant.McCune-Albright syndrome and disorders due to activating mutations of GNAS1.Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Somatostatin agonists for treatment of acromegaly.Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood.Octreotide LAR: safety and tolerability issues.Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.Medical therapy in acromegaly.Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.Octreotide long-acting repeatable for acromegaly.Octreotide for acromegaly treatment: a reappraisal.Pharmacological treatment of acromegaly: its place in the overall therapeutic approach.Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.Update on prognostic factors in acromegaly: Is a risk score possible?Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.Treatment of acromegaly in the era of personalized and predictive medicine.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy.The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study.Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly.
P2860
Q26777682-2B0B12C4-E278-448D-985E-C140A5F591B2Q28730120-A5197857-1CAE-4689-B357-1C2FC7F1CE31Q33595081-0DA9355C-DE03-4455-B3A7-06E6A915AEA8Q33772673-1511C39B-25EC-4A99-8C65-13E20ABFC2ECQ33858344-8A92A678-8CB9-4B1A-A39A-08B12BE0BFC2Q34901376-F8824948-7969-45F6-B7EB-87F76625D3A6Q35895856-277C83ED-5CD1-4C03-82CD-1B3714ADA18AQ35987482-9C6F49CA-20A8-4E82-8188-F2E5453B263BQ35987499-3A50041C-C065-4E9D-B8B7-E005816D637CQ36301564-74A3AF27-590B-4215-8ED7-6F390C99811EQ36302865-ADF9517E-2B72-4EFE-BF5C-B75FB2167A38Q36328066-3E45CCF9-767D-49A1-B371-ED439A61C3D5Q36380875-64B85740-A516-43F1-9890-76E023530069Q36428225-32A8B967-EDD7-4192-9470-FA05242891E6Q36509265-424B1684-46BC-4A54-BF71-2BE50FC82071Q36605363-4FE1CB96-5E30-4DAC-981E-E12A4290B3A0Q36626503-CA953EF4-348D-496B-BE27-E93F38FC19B8Q36919554-D08ADABA-1A7C-415D-9EC2-F3529F106A51Q36920317-699CD95F-445B-461E-AD32-641E196D3E90Q36971542-B5E62B0E-FAA7-4AC9-ABFA-427FB8389FE5Q37029532-BE7587C9-C083-41AB-8BB1-4F0ABCDF6A9CQ37055643-AE2E0327-37FA-4D3A-BF68-64DA387B831EQ37139774-A09CE816-30EE-4067-8A4E-981697050CE9Q37425200-E7C13DDD-BF90-4AF9-97D5-381A7868FA46Q37649647-355017D8-99D5-4D06-8BF4-2990A6E816A4Q37663006-F9185D5F-6EEF-40CA-A4DA-91C2B27A2F55Q37859250-5DBA20DB-DEFE-45D5-AD44-A0010F834B3CQ37941521-C8D7DAF4-F9AC-4F61-A975-37735CFA10CDQ37990556-9650DDE2-6E2A-4EEB-8EAB-B5FEC0DEF8B5Q38152458-83FEED9F-419F-41B9-A8B4-80E4BBA4E4E9Q38179982-1D10CEA5-9C34-4411-94D6-F563EB575796Q38185306-34A9FC5A-33A2-4AD6-A8C6-D561EC344740Q38214473-1684383B-4039-413C-A249-4C85806B314FQ38222170-9C87E6E0-CBE1-42D6-9672-E1914EB3637EQ38340014-168E16E1-AE01-4C31-8D6A-8CF370084AB8Q38683309-E1FD6F9C-2762-4D21-90F8-01FB331498D3Q40500085-C9B9286B-A54D-4C93-957A-33C9CA4F4CD7Q41004401-48D5472E-5F5A-4138-A45F-E16441D4C8CDQ42378746-242073DF-EBDE-4BC1-8DAB-2ED2857C881AQ42448382-4A698E1F-FBCB-48B4-B836-C97D0522F557
P2860
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Four-year treatment with octre ...... e value of short-term results?
@en
Four-year treatment with octre ...... e value of short-term results?
@nl
type
label
Four-year treatment with octre ...... e value of short-term results?
@en
Four-year treatment with octre ...... e value of short-term results?
@nl
prefLabel
Four-year treatment with octre ...... e value of short-term results?
@en
Four-year treatment with octre ...... e value of short-term results?
@nl
P2093
P356
P1476
Four-year treatment with octre ...... e value of short-term results?
@en
P2093
Alberto M Pedroncelli
Daniela Dallabonzana
Giorgio Pagani
Giovanni Lasio
Marcella Montini
Mascia Albizzi
Michela Barausse
Renato Cozzi
Sandro Lodrini
P304
P356
10.1210/JC.2003-030110
P407
P577
2003-07-01T00:00:00Z